Comparative analysis of allowable total error specifications for coagulation factor assays utilizing China National External quality assessment scheme data and biological variation data.

IF 3.2 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Clinica Chimica Acta Pub Date : 2025-01-16 DOI:10.1016/j.cca.2025.120141
Chengshan Xu, Zhongli Du, Gaofeng Hu, Yating Ma, Chenbin Li
{"title":"Comparative analysis of allowable total error specifications for coagulation factor assays utilizing China National External quality assessment scheme data and biological variation data.","authors":"Chengshan Xu, Zhongli Du, Gaofeng Hu, Yating Ma, Chenbin Li","doi":"10.1016/j.cca.2025.120141","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>It is necessary and challenging to establish reasonable and feasible total error specifications for coagulation factor assays for quality control and assessment. The aim of this study is to establish new total error specifications for coagulation factor assays by combining External Quality Assessment data with reliable biological variation data.</p><p><strong>Methods: </strong>Data from China National External Quality Assessment Scheme (28,408 results from 1,381 laboratories) were analyzed, stratifying External Quality Assessment data by reference intervals to establish concentration-dependent total error specifications. A \"state-of-the-art\" total error was defined at 80% best results of the participants. Then these specifications were compared with biological variation-derived total error to determine recommended total error specifications for different concentration levels.</p><p><strong>Results: </strong>None of the measurands could meet biological variation-derived optimum total error. Eight parameters (FII, FVIII, FX at both high and low levels; FVII and FIX at high level) reached the desirable criteria. Only FXI at low level can't met the minimum criteria.</p><p><strong>Conclusions: </strong>The establishment of total error specifications for coagulation factor assays should be set separately according to different concentration levels and attainability of current testing technologies. Setting total error specifications should also consider clinical requirements and regulatory standards across different regions. Analyte concentration significantly influences laboratory performance, particularly for low-concentration coagulation factors. Total error specifications need updated periodically in the further.</p><p><strong>Abbreviations: </strong>Tea, allowable total error; BV, biological variation; SOTA, state of the art; EQAS, External quality assessment schemes; ME, measurement error; RIs, reference intervals; BIVAC, Biological Variation Data Critical Appraisal Checklist; QIs, quality items; EFLM, European Federation of Clinical Chemistry and Laboratory Medicine; APS, analytical quality specifications; ISO, International Organization for Standardization; EQA, External quality assessment; PT, proficiency testing; RCPA, Royal College of Pathologists of Australasia; RfB, Reference Institute for Bioanalytics; ECAT, External Quality Control for Assays and Tests.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"568 ","pages":"120141"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cca.2025.120141","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: It is necessary and challenging to establish reasonable and feasible total error specifications for coagulation factor assays for quality control and assessment. The aim of this study is to establish new total error specifications for coagulation factor assays by combining External Quality Assessment data with reliable biological variation data.

Methods: Data from China National External Quality Assessment Scheme (28,408 results from 1,381 laboratories) were analyzed, stratifying External Quality Assessment data by reference intervals to establish concentration-dependent total error specifications. A "state-of-the-art" total error was defined at 80% best results of the participants. Then these specifications were compared with biological variation-derived total error to determine recommended total error specifications for different concentration levels.

Results: None of the measurands could meet biological variation-derived optimum total error. Eight parameters (FII, FVIII, FX at both high and low levels; FVII and FIX at high level) reached the desirable criteria. Only FXI at low level can't met the minimum criteria.

Conclusions: The establishment of total error specifications for coagulation factor assays should be set separately according to different concentration levels and attainability of current testing technologies. Setting total error specifications should also consider clinical requirements and regulatory standards across different regions. Analyte concentration significantly influences laboratory performance, particularly for low-concentration coagulation factors. Total error specifications need updated periodically in the further.

Abbreviations: Tea, allowable total error; BV, biological variation; SOTA, state of the art; EQAS, External quality assessment schemes; ME, measurement error; RIs, reference intervals; BIVAC, Biological Variation Data Critical Appraisal Checklist; QIs, quality items; EFLM, European Federation of Clinical Chemistry and Laboratory Medicine; APS, analytical quality specifications; ISO, International Organization for Standardization; EQA, External quality assessment; PT, proficiency testing; RCPA, Royal College of Pathologists of Australasia; RfB, Reference Institute for Bioanalytics; ECAT, External Quality Control for Assays and Tests.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用中国国家外部质量评价方案数据和生物变异数据对凝血因子试验允许总误差规范进行比较分析。
背景:建立合理可行的凝血因子测定总误差规范以进行质量控制和评价是必要的,也是具有挑战性的。本研究的目的是通过结合外部质量评估数据和可靠的生物变异数据,建立新的凝血因子测定的总误差规范。方法:分析中国国家外部质量评价体系数据(1381个实验室28408份结果),采用参考区间对外部质量评价数据进行分层,建立浓度相关的总误差规范。“最先进”的总误差定义为参与者的最佳结果的80%。然后将这些指标与生物变异衍生的总误差进行比较,以确定不同浓度水平的推荐总误差指标。结果:所有指标均不能满足由生物变异引起的最佳总误差。8个参数(FII, FVIII, FX在高电平和低电平;FVII和FIX(高水平)达到理想标准。只有低水平的FXI不能满足最低标准。结论:凝血因子试验总误差标准的建立应根据不同浓度水平和现有检测技术的可得性单独设置。设定总误差规范还应考虑不同地区的临床要求和监管标准。分析物浓度显著影响实验室性能,特别是低浓度凝血因子。今后总错误规范需要定期更新。缩写:茶,允许总误差;BV,生物变异;SOTA,最先进的;EQAS,外部质量评估方案;ME:测量误差;RIs,参考区间;生物变异数据关键评估清单;QIs,质量项目;欧洲临床化学和检验医学联合会;APS,分析质量规范;ISO,国际标准化组织;EQA,外部质量评估;PT,能力测试;澳大利亚皇家病理学会;生物分析参考研究所;测定和试验的外部质量控制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinica Chimica Acta
Clinica Chimica Acta 医学-医学实验技术
CiteScore
10.10
自引率
2.00%
发文量
1268
审稿时长
23 days
期刊介绍: The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.
期刊最新文献
Clinicopathological characteristics of patients with low titer anti-phospholipase A2 receptor antibodies verified by indirect immunofluorescence assay. MiR-363: A potential biomarker of kidney diseases. Osteocalcin: A bone protein with multiple endocrine functions. Crispr-cas biosensing for rapid detection of viral infection. Biosensors for early stroke detection.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1